Macquarie Group’s Arbutus Biopharma ABUS Stock Holding History

Macquarie Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,792	Closed	-$9K	–	2148
2017 Q4	$9K	Buy	+1,792	New	+$10.5K	﹤0.01%	2270

Other funds holding ABUS

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Macquarie Group's ABUS Position: Q1 2018 in Review

Macquarie Group sold out of Arbutus Biopharma (ABUS) in Q1 2018, closing a stake of 1,792 shares — an estimated $9K sold.

Macquarie Group first reported a position in ABUS in Q4 2017 and held it in 1 quarter. The position peaked at $9K in Q4 2017. 50 funds tracked by Wall St. Rank hold ABUS as of Q1 2018.

Macquarie Group reported no remaining Arbutus Biopharma position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 1,792 Arbutus Biopharma shares in Q1 2018, an estimated $9K.
Macquarie Group first reported a position in Arbutus Biopharma in Q4 2017 and held it in 1 quarter.
Macquarie Group's Arbutus Biopharma position peaked at $9K in Q4 2017.
50 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.